מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
ZOLMITRIPTAN
LABORATOIRE RIVA INC.
N02CC03
ZOLMITRIPTAN
2.5MG
TABLET
ZOLMITRIPTAN 2.5MG
ORAL
6/30
Prescription
SELECTIVE SEROTONIN AGONISTS
Active ingredient group (AIG) number: 0134381001; AHFS:
CANCELLED POST MARKET
2019-03-05
PRODUCT MONOGRAPH PR (ZOLMITRIPTAN FILM-COATED TABLETS) RIVA-ZOLMITRIPTAN 2.5 MG 5-HT1 RECEPTOR AGONIST MIGRAINE THERAPY LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Québec, Canada. J7C 3V4 www.labriva.com Date of Revision: August 25, 2015 Submission Control #: 186807 _RIVA-ZOLMITRIPTAN Product Monograph _ _Page 2 of 36 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................23 PART II: SCIENTIFIC INFORMATION ...............................................................................24 PHARMACEUTICAL INFORMATION ..........................................................................24 CLINICAL TRIALS ..........................................................................................................25 DETAILED PHARMACOLOGY ...................... קרא את המסמך השלם